Early Anti-TNFα Therapy Cuts Perianal Fistula Complications in Pediatric Crohn Disease
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 3, 2025 -- For pediatric patients with Crohn disease, early anti-tumor necrosis factor-alpha (anti-TNFα) therapy is beneficial in preventing the development of perianal fistula complications (PFCs), according to a study published online Dec. 12 in Gut.
Jeremy Adler, M.D., from the University of Michigan in Ann Arbor, and colleagues examined whether early anti-TNFα therapy prevents PFCs in pediatric patients with Crohn disease. Participants had never experienced PFCs 30 days after study enrollment. Nearest-neighbor propensity score-matched triad analyses were conducted. A total of 447 matched patients without perianal fistula were included in the study.
The researchers observed a significant association for the presence of nonpenetrating perianal lesions (large skin tags, ulcers, and/or fissures) with PFC development (odds ratio, 4.08). The odds of PFCs were significantly reduced in association with early anti-TNFα therapy (odds ratio, 0.18). Among patients with perianal lesions, the odds of PFC development were further reduced in association with anti-TNFα therapy (odds ratio, 0.055). A reduced risk for PFCs was not seen in association with any other treatment group.
"Based on these findings, which corroborate prior studies, early anti-TNFα therapy should be recommended for pediatric patients at increased risk in order to prevent PFCs, serious complications, which are difficult to treat," the authors write. "The specific timing of how early anti-TNFα therapy should be introduced for different patient populations requires further study."
One author disclosed receipt of consulting fees from Janssen Research & Development.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Spatiotemporal Mapping IDs Four Stages of Inflammatory Bowel Disease Evolution
TUESDAY, May 6, 2025 -- Machine learning has enabled spatiotemporal mapping of the four stages of the evolution of inflammatory bowel disease (IBD), according to a study published...
Chronic Conditions and Their Age of Onset Predict Health Trajectory in IBD
MONDAY, March 24, 2025 -- Among people with inflammatory bowel disease (IBD), conditions developed at or before age 60 years and their age of onset are important for predicting...
IBD Activity May Increase Risk for Clostridioides Difficile Infection
WEDNESDAY, March 5, 2025 -- For patients with inflammatory bowel disease (IBD), risk factors associated with Clostridioides difficile infection (CDI) include recent diagnosis...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.